What Generate Biomedicines does

Generate Biomedicines (Nasdaq: GENB) is a clinical-stage generative biology company founded in 2018 and incubated by Flagship Pioneering, headquartered in Somerville, Massachusetts with additional research operations in Andover. The company operates The Generate Platform, a continuous machine-learning-driven loop (Generate → Build → Measure → Learn) that integrates ML, biological engineering and medicine to design de novo protein therapeutics rather than screen or modify natural proteins. The platform's flagship technical asset is Chroma, a proprietary generative diffusion model for protein and protein-complex design that was published in Nature in 2023 and experimentally validated across 310 designed proteins (backbone RMSD ~1.0 Å versus crystal structures); Chroma code is open-sourced on GitHub with downloadable model weights. Four best-in-class CryoEM microscopes support high-throughput structural feedback, and the platform has cumulatively generated, built and tested more than 42,000 proteins.

The company's clinical pipeline is anchored by GB-0895, a long-acting anti-TSLP antibody for severe asthma (currently in two global Phase 3 trials enrolling ~1,600 patients, engineered for twice-yearly subcutaneous dosing) and a Phase 1 program in COPD. Other disclosed assets include GB-4362, an MMAE-neutralizing monoclonal antibody with FDA Fast Track designation intended for combination use with MMAE-based ADCs; GB-5267, an IL-18 armored CAR T-cell therapy targeting MUC16 for metastatic ovarian cancer in a 50/50 collaboration with Roswell Park; and the deprioritized GB-0669 SARS-CoV-2 antibody (first-in-human data published on medRxiv, October 2025). GB-0895 is, per the company's own materials and third-party press, the first AI-derived antibody to enter Phase 3 clinical trials.

Generate Biomedicines generates revenue exclusively through enterprise R&D collaboration agreements with large pharmaceutical partners — chiefly Amgen (up to $1.9B total potential value across six programs since January 2022) and Novartis (up to $1B+ across multiple programs since September 2024) — recognizing $31.9M in collaboration revenue in FY2025 (up 56% YoY) and approximately $110M in cumulative collaboration payments to date. The company is pre-commercial with no product sales; it raised approximately $805M in private capital prior to its February 2026 Nasdaq IPO, which added $400M of gross proceeds and brought pro-forma cash to $516.6M as of March 31, 2026, supporting runway into the first half of 2028. Flagship Pioneering remains the largest shareholder at approximately 49% post-IPO.

Name

Generate Biomedicines

Legal name

Generate Biomedicines, Inc.

Website

https://generatebiomedicines.com

Company type

Public

Founded year

2018

Operating status

Ipo

Headcount range

251–500 employees

Short description

Generate Biomedicines is a clinical-stage biotech that uses its proprietary Chroma generative AI model and The Generate Platform to design de novo protein therapeutics, with lead asset GB-0895 (the first AI-derived antibody in Phase 3) for severe asthma. It monetizes via multi-program R&D collaborations with large pharma, notably Amgen (up to $1.9B) and Novartis (up to $1B+).

Ownership category

akta.pro rank

Headquarters

HQ city

Somerville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Collaboration revenue (pharma partnerships): Revenue recognized from R&D collaborations with major pharmaceutical partners under multi-target discovery agreements (Amgen — 6 programs since Jan 2022, up to $1.9B; Novartis — multiple discovery-stage programs since Sept 2024, up to $1B+). Generate reported $31.9 million in collaboration revenue for 2025, up 56% year-over-year, and has cumulatively received approximately $110 million in collaboration payments from Amgen and Novartis.
2. Equity capital and IPO proceeds: Capital formation through venture financings (Series B $370M in Nov 2021; Series C $273M in 2023; cumulative ~$805M private financing) and IPO ($400M gross proceeds completed Feb 27, 2026 on NASDAQ under GENB at $16/share); cash position of $516.6M as of March 31, 2026 with runway projected into first half of 2028.
3. Future product sales (pre-commercial): No commercial product revenue as of Q1 2026; clinical-stage company with lead asset GB-0895 in Phase 3 trials for severe asthma; revenue of $7.2M in Q1 2026 declined from $8.8M in Q1 2025, reflecting collaboration-driven business.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Generate Biomedicines operates a generative biology platform that uses machine learning (the Chroma diffusion model) to design de novo protein therapeutics rather than screening or modifying natural proteins. The company sells its discovery and development capabilities through multi-program enterprise collaborations with large pharmaceutical partners (Amgen, Novartis) and is advancing its own clinical-stage pipeline, including the Phase 3 anti-TSLP antibody GB-0895 for severe asthma and earlier-stage candidates in oncology.

Product overview

Generate Biomedicines operates a single integrated generative biology platform with multiple clinical-stage therapeutic candidates as outputs. The architecture centers on The Generate Platform, an AI-driven continuous generate-build-measure-learn loop underpinned by the Generative Biology methodology and the proprietary Chroma generative protein model. Platform outputs feed a pipeline of protein-based therapeutic candidates including the Phase 3 anti-TSLP antibody GB-0895 (lead asset for severe asthma, with a Phase 1 program in COPD), the Phase 1 MMAE-neutralizing antibody GB-4362 (FDA Fast Track designated), the preclinical IL-18 armored CAR T-cell therapy GB-5267 (MUC16, partnered with Roswell Park), and additional confidential preclinical programs including next-generation ADCs. The platform also supports strategic platform collaborations with Amgen (six programs, since January 2022) and Novartis (multiple programs, since September 2024).

Differentiator

Problem solved

Functional benefit

Brands

• Generate:Chroma: A generative model for protein design that creates new protein molecules based on geometric and functional programming instructions.
• Generative Biology®
• The Generate Platform™

Products and services

• The Generate Platform
• Chroma
• GB-0895
• GB-4362
• GB-5267
• GB-0669

Quantifiable outcome

• First AI-derived antibody (GB-0895) progressed from concept to Phase 3 trials in five years
• +7 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability4 records

Feature6 records

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

• NovartisflagshipStrategic or Co-development Partner · 1 September 2024Multi-program discovery collaboration announced September 2024 across multiple discovery-stage protein therapeutics programs; total potential deal value exceeds $1 billion per company and Klover analysis. Generate and Novartis publicly disclosed the collaboration across multiple industry sources.
• AmgenflagshipStrategic or Co-development Partner · 1 January 2022Multi-program protein therapeutics collaboration originally announced January 2022 for five programs and expanded in January 2024 to add a sixth program; total potential deal value of up to $1.9 billion across six programs. Collaboration revenue is included in the cumulative $110M received from Amgen/Novartis referenced at IPO. Generate and Amgen publicly disclosed the collaboration through the IPO S-1 and corporate filings.
• Roswell Park Comprehensive Cancer CentercoreStrategic or Co-development Partner50/50 collaboration on GB-5267, an IL-18 armored CAR T-cell therapy targeting MUC16 for metastatic ovarian cancer. IND 'study may proceed' granted December 2025; first patient dosing planned for H2 2026 per Morgan Stanley analyst coverage and pipeline page.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerStrategic collaboration in oncology and CAR-T cells announced 2023 to develop novel therapeutics by combining Generate's generative AI platform with MD Anderson's translational and clinical research capabilities.
• Flagship PioneeringflagshipStrategic or Co-development PartnerFounding incubator and largest shareholder; founded Generate in 2018. Flagship Pioneering holds approximately 48.76% post-IPO via Noubar Afeyan and remains a 57% pre-IPO shareholder; board chair Noubar Afeyan (Founder/CEO of Flagship) plus Flagship partners Paul Parker and Rupert Vessey sit on Generate's board. Generated >$750M prior to IPO across multiple financing rounds.
• ModernaminorStrategic or Co-development PartnerAffiliation via board director Stéphane Bancel (CEO of Moderna and Flagship Pioneering venture partner). No commercial partnership is publicly disclosed.

Scale indicators18 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Insilico Medicine: AI-driven drug discovery company combining generative models, biology and chemistry to identify novel targets and design small molecules; one of the most prominent and well-funded generative biology peers to Generate, pursuing a comparable pharma BD and pipeline strategy.
• Recursion Pharmaceuticals: Clinical-stage AI-enabled biotech combining high-throughput wet-lab experimentation with ML to discover and develop therapeutics; directly comparable as a publicly-traded AI drug-discovery platform with both pipeline assets and large pharma partnerships (e.g., Roche, Bayer).
• Schrödinger: Physics-based computational platform for molecular design combining ML with simulation for drug and materials discovery; operates a hybrid software-plus-co-discovery business model with big-pharma collaborations, comparable to Generate's platform-plus-partnership GTM.
• Isomorphic Labs: Alphabet-founded AI drug discovery company building on DeepMind's AlphaFold to design novel therapeutics; closest large-cap peer pursuing generative protein/small-molecule design with major pharma partnerships (Eli Lilly, Novartis).
• Absci: Generative AI drug creation company combining a proprietary E. coli-based synthetic biology platform with deep learning models for antibody and protein therapeutic design; a direct platform competitor in AI-designed biologics with pharma collaborations.

Emerging players

• Xaira Therapeutics: Well-funded (>$1B launch) AI drug discovery company founded in 2023 leveraging generative models to design therapeutics; comparable as a recent entrant with similar ambitions and large capital base pursuing generative biology for protein and small molecule discovery.
• Cradle Bio: AI-driven protein engineering company building generative models for designing new proteins, with partnerships including Novo Nordisk; comparable as an emerging generative-protein-design peer pursuing a similar BD-plus-platform strategy.
• Profluent Bio: AI protein design company founded by protein-ML researchers applying large language models to protein engineering, with a focus on gene editing and therapeutics; comparable as a frontier generative-protein-design peer with adjacent use cases.
• Relation Therapeutics: AI-enabled drug discovery company combining single-cell genomics, graph ML and lab-in-the-loop experimentation to discover novel therapeutics; comparable as a wet-lab-and-ML platform biotech pursuing similar indication-agnostic discovery partnerships.
• EvolutionaryScale: Frontier AI research company building large-scale models for biology and protein design (ESM3); comparable as a foundational generative-protein-model peer with ambitions spanning therapeutic and non-therapeutic protein design.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/generate_biomed
• GitHubgithub.com/generatebio/chroma
• YouTubeyoutube.com/@GenerateBiomedicines
• LinkedInlinkedin.com/company/generate-biomedicines-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Generate Biomedicines